正面交锋调查：Sema4（SMFR）与竞争对手

Sema4 (NASDAQ:SMFR – Get Rating) is one of 33 publicly-traded companies in the "Health services" industry, but how does it weigh in compared to its rivals? We will compare Sema4 to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends.

Profitability

This table compares Sema4 and its rivals' net margins, return on equity and return on assets.

Get Sema4 alerts:

Volatility & Risk

Sema4 has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Sema4's rivals have a beta of 1.19, meaning that their average share price is 19% more volatile than the S&P 500.

Insider and Institutional Ownership

48.6% of shares of all "Health services" companies are owned by institutional investors. 21.6% of shares of all "Health services" companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Sema4 and its rivals gross revenue, earnings per share (EPS) and valuation.

Sema4's rivals have higher revenue and earnings than Sema4. Sema4 is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations for Sema4 and its rivals, as reported by MarketBeat.com.

Sema4 currently has a consensus price target of $2.67, indicating a potential upside of 858.20%. As a group, "Health services" companies have a potential upside of 101.57%. Given Sema4's higher possible upside, equities research analysts plainly believe Sema4 is more favorable than its rivals.

Summary

Sema4 rivals beat Sema4 on 7 of the 12 factors compared.

Sema4 Company Profile

(Get Rating)

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.

Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with MarketBeat.com's FREE daily email newsletter.